Literature DB >> 34014537

Non-Hodgkin Lymphoma Metabolism.

Brian James Kirsch1,2, Shu-Jyuan Chang3, Michael James Betenbaugh2, Anne Le4,5.   

Abstract

Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of lymphoid neoplasms with different biological characteristics. About 90% of all lymphomas in the United States originate from B lymphocytes, while the remaining originate from T cells [1]. The treatment of NHLs depends on the neoplastic histology and stage of the tumor, which will indicate whether radiotherapy, chemotherapy, or a combination is the best suitable treatment [2]. The American Cancer Society describes the staging of lymphoma as follows: Stage I is lymphoma in a single node or area. Stage II is when that lymphoma has spread to another node or organ tissue. Stage III is when it has spread to lymph nodes on two sides of the diaphragm. Stage IV is when cancer has significantly spread to organs outside the lymph system. Radiation therapy is the traditional therapeutic route for localized follicular and mucosa-associated lymphomas. Chemotherapy is utilized for the treatment of large-cell lymphomas and high-grade lymphomas [2]. However, the treatment of indolent lymphomas remains problematic as the patients often have metastasis, for which no standard approach exists [2].

Entities:  

Keywords:  Aerobic glycolysis; Fatty acid metabolism; Gene expression; Glutamine metabolism; Heterogeneous malignant lymphomas; Lactic acidosis; PI3K/AKT/mTOR pathway; [18F]FDG PET/CT

Mesh:

Year:  2021        PMID: 34014537     DOI: 10.1007/978-3-030-65768-0_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  81 in total

Review 1.  Pathogenesis of follicular lymphoma.

Authors:  Robert Kridel; Laurie H Sehn; Randy D Gascoyne
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 2.  Metabolic Reprogramming of Immune Cells in Cancer Progression.

Authors:  Subhra K Biswas
Journal:  Immunity       Date:  2015-09-15       Impact factor: 31.745

3.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

4.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.

Authors:  J S Newman; I R Francis; M S Kaminski; R L Wahl
Journal:  Radiology       Date:  1994-01       Impact factor: 11.105

Review 5.  Non-Hodgkin lymphoma.

Authors:  Kate R Shankland; James O Armitage; Barry W Hancock
Journal:  Lancet       Date:  2012-07-25       Impact factor: 79.321

Review 6.  Transformation in follicular lymphoma: biology, prognosis, and therapeutic options.

Authors:  Eric Wong; Michael Dickinson
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

7.  Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.

Authors:  Alyssa Bouska; Timothy W McKeithan; Karen E Deffenbacher; Cynthia Lachel; George W Wright; Javeed Iqbal; Lynette M Smith; Weiwei Zhang; Can Kucuk; Andrea Rinaldi; Francesco Bertoni; Jude Fitzgibbon; Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Bhavana J Dave; Randy D Gascoyne; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Jan Delabie; Elaine S Jaffe; Rita M Braziel; Joseph M Connors; Louis M Staudt; Wing-Chung Chan
Journal:  Blood       Date:  2013-09-13       Impact factor: 22.113

8.  Application of metabolomics technologies toward cancer prognosis and therapy.

Authors:  Giang Hoang; Sunag Udupa; Anne Le
Journal:  Int Rev Cell Mol Biol       Date:  2019-08-07       Impact factor: 6.420

9.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.

Authors:  Jessica Okosun; Csaba Bödör; Jun Wang; Shamzah Araf; Cheng-Yuan Yang; Chenyi Pan; Sören Boller; Davide Cittaro; Monika Bozek; Sameena Iqbal; Janet Matthews; David Wrench; Jacek Marzec; Kiran Tawana; Nikolay Popov; Ciaran O'Riain; Derville O'Shea; Emanuela Carlotti; Andrew Davies; Charles H Lawrie; Andras Matolcsy; Maria Calaminici; Andrew Norton; Richard J Byers; Charles Mein; Elia Stupka; T Andrew Lister; Georg Lenz; Silvia Montoto; John G Gribben; Yuhong Fan; Rudolf Grosschedl; Claude Chelala; Jude Fitzgibbon
Journal:  Nat Genet       Date:  2013-12-22       Impact factor: 38.330

10.  Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.

Authors:  Elisa Oricchio; Giovanni Ciriello; Man Jiang; Michael H Boice; Jonathan H Schatz; Adriana Heguy; Agnes Viale; Elisa de Stanchina; Julie Teruya-Feldstein; Alyssa Bouska; Tim McKeithan; Chris Sander; Wayne Tam; Venkatraman E Seshan; Wing-Chung Chan; R S K Chaganti; Hans-Guido Wendel
Journal:  J Exp Med       Date:  2014-06-09       Impact factor: 14.307

View more
  2 in total

Review 1.  Metabolic Regulation of Fibroblast Activation and Proliferation during Organ Fibrosis.

Authors:  Sudan Wang; Yan Liang; Chunsun Dai
Journal:  Kidney Dis (Basel)       Date:  2022-03-03

Review 2.  Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment.

Authors:  Abdullah Alfaifi; Salem Bahashwan; Mohammed Alsaadi; Hafiz Malhan; Aqeel Aqeel; Waiel Al-Kahiry; Hussein Almehdar; Ishtiaq Qadri
Journal:  Diagnostics (Basel)       Date:  2022-02-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.